Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
HUH?
FYI:
From The New York Times:
Companies Rush to Develop %2??Utterly Transformative%2?? Gene Therapies
Gene therapy for cancer is becoming a reality but works best for blood cancers like leukemia and not yet in more common ones like lung cancer.
https://www.nytimes.com/2017/07/23/health/gene-therapy-cancer.html?mwrsm=Email
Any idea on how many Dewars a typical patient would typically go through during pre and post treatment? I know there may be other cancers/diseases that this treatment may be used for in the future, but the attached article predicts that it may only be used on approximately 900 cases per year.
https://www.statnews.com/2017/07/12/novartis-car-t-fda-approval/
Anyone familiar with this site?
http://thestreetsweeper.org/undersurveillance/Cryoport__CYRX___Time_to_Ice_This_Stock
Anyone familiar with this site?
http://thestreetsweeper.org/undersurveillance/Cryoport__CYRX___Time_to_Ice_This_Stock
Me too, I only post on porn sites!
If you scroll down from the article to the comment section you will see a post praising CYRX as the solution to the potential problems the article presented.
Even without a buyout this stock could easily be $20 in 2019. Another potential suitor could be Amazon.
WOW,THAT LONG? Did anyone see the 61,900 share buy at the close and 26,140 after the bell, both at $4.679
When these companies put out a price target is that their estimate of what the price will be in a year, 6 months or ?
Found this today on Kite Connect white glove service. Cryoport name not used but we all know who makes the temperature controlled containers.
'Kite plans to offer doctors and patients what it describes as a “white glove” service branded as Kite Connect, which promises to manage the entire process from booking the patient in for their first hospital visit to transporting their cells in temperature-controlled containers with nitrogen ice. Customers will be able to follow the progress of their cells online and receive notifications informing them when they are about to leave the company’s factory [...] To help build their laboratories and computer systems, Juno, Novartis and Kite have enlisted General Electric, the industrial conglomerate. [...] Phil Vanek, general manager of GE’s cell therapy division, says the company wants to “industrialise” Car-T manufacturing. “The process today is not 2017 technology, it’s 2010 technology ... that’s fine for dealing with academic centres that handle five to 10 patients a year, but we have to figure out a process for tens of thousands.”'
Financial Times
Thanks, I wasn't aware of his past bashing. I do remember at least 5 years ago someone at the Street.com wrote a very positive article on Cryoport and the stock had a very nice upswing. But that was in the "Good Old Days".
Not familiar with the author but I felt it was very well written. What is the basis for your dislike?
2.7 million
"I guess my question is how long should the shareholders of CYRX standby and wait for this growth Jerry said we would see 12-18 months ago?"
I have held out for supposed growth for close to 10 years and have put a deadline of Dec.31,2017. Even if I see growth I will not hold this stock past 2018 without positive earnings.
2.37 million
Hopefully we see a better than expected quarterly report in the next couple weeks
Big jump in volume near the close today. 30,000 share transaction at 4pm.
Anyone know anything about this company? I found this on another site.
Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
Share1Print
March 30, 2017 18:30 ET | Source: Osiris Therapeutics, Inc.
COLUMBIA, Md., March 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues at ambient temperatures.
Historically, cryopreservation was the only available method that allowed for long-term preservation of living cells and tissues. However, cryopreservation requires ultra-low-temperature freezers and dry ice or liquid nitrogen for storage, which limits the widespread use of cellular therapies. To address this limitation, Osiris has developed Prestige™ Lyotechnology. Unlike all other known lyophilization methods, Prestige™ Lyotechnology enables the preservation of living cells within tissues while stored at ambient temperatures. Moreover, the manufacturing of lyopreserved living tissues with Prestige™ Lyotechnology is scalable and can be applied to many different cell and tissue types. Placental products will be the focus of the Company’s first application of Prestige™ Lyotechnology.
“This novel technology developed by Osiris will benefit the entire field of cellular therapies. It is expected to accelerate development, commercialization and widespread use of living cell and tissue therapies,” said Alla Danilkovitch, Chief Scientific Officer at Osiris. “Through more than two decades of basic and clinical research, Osiris has not only defined the science and potential of cellular regenerative therapies, but has also created a body of work, advancing the medical community’s understanding of cellular technology. With the introduction of Prestige™ Lyotechnology, Osiris is bringing these innovative cellular therapies to more patients to address a wide range of unmet medical needs.”
The Osiris’s Prestige™ Lyotechnology is featured in tomorrow’s online publication of Osiris’s profile in the scientific journal Nature (www.nature.com), entitled “Innovation on the shelf: solving the puzzle of live-cell preservation”. The print version of this article will appear in the special annual “MedTech Dealmakers” issue of Nature Medicine, Nature Biotechnology and Nature Reviews Drug Discovery in May. Nature is the world’s most highly cited international, interdisciplinary science journal.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing, and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world's first approved stem cell drug, the Company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine — including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in wound care, orthopedics, and sports medicine, including Grafix®, Stravix™, BIO4 ™, and Cartiform®. Osiris, Grafix, Stravix and Cartiform are trademarks of Osiris Therapeutics, Inc., and BIO4 is a trademark of Howmedica Osteonics Corp. More information can be found on the Company’s website, www.Osiris.com.
From Endpoint news yesterday:
Fresh turmoil inside Novartis’ revamped CAR-T organization as top exec jumps ship
by john carroll
March 30, 2017 12:37 PM EDT
Updated: March 31, 2017 06:07 AM
There’s more turmoil to report from inside Novartis’ CAR-T camp.
On Friday Karen Walker will leave a senior position in charge of CMC/manufacturing of CAR-Ts for Novartis in exchange for a new position she’s taking at Seattle Genetics, Endpoints News has learned.
Walker — the VP Global Head Cell and Gene Therapies Technical Development and Manufacturing at Novartis — was one of three senior execs put in charge of the cell and gene therapy initiative at the company last fall, according to sources close to the company, after a bruising restructuring over the summer in which the unit was chopped up and absorbed inside a huge R&D organization. Samuele Butera was put in charge of the commercial/business aspect of the group while David Lebwohl handles clinical ops.
“Karen Walker will join Seattle Genetics as Vice President of Global Quality in mid-April,” confirmed a spokesperson for Seattle Genetics.
I contacted Eric Althoff, a spokesperson for Novartis, Wednesday night, but after acknowledging my query he did not follow up. Althoff has declined to respond to a followup query.
Novartis has been bleeding talent throughout its global organization for the past year. Walker’s departure, though, comes at a particularly critical stage for Novartis, just days after the pharma giant gained a priority review for CTL019, putting it on a short path to perhaps the first historic approval for a CAR-T.
Last summer Endpoints broke the story about Novartis’ reorganization in CAR-T, which led the group’s top exec, Usman ‘Oz’ Azam, to leave Novartis. About 120 staffers were also terminated as the separate group was pulled back into the R&D structure.
Novartis has kept up a neck-and-neck race with Kite on the lead program, which has its own pioneering CAR-T headed to the FDA.
Manufacturing in this field is critical. To make this therapy, physicians extracts cells from cancer patients and then reengineer them with a chimeric antigen receptor to guide them to attack cancer cells. The revised cells are then injected back into patients. To be competitive, a company has to prove not only that they know how to make the therapy, they also have to be able to turn it around quickly for use.
Get endpoints news in your inbox
News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.
quick subscribe
Catalent Pharma Solutions
Read next
latest
UPDATED: Kite Pharma hits its Q1 deadline on filing a BLA for its pioneering CAR-T, posts improved data
3 hours
Dems fire off a silly pricing bill; What's wrong with Novartis?
9 hours
Halozyme slides on an early futility failure for its lead cancer therapy
11 hours
See all latest
featured
Merck, Incyte map a Phase III pipeline of their own for a frontline combo of Keytruda and epacadostat
March 31, 2017
Excellent articles on this site regarding the drug industry. Free to subscribe. http://get.endpts.com/
In all fairness to management how do they give future estimates when 18 clinical trials are in Phase 3 and they may be worth 2-20 million each IF APPROVED. That's a big gap, 2-20 million.
I'm as pissed off as anyone with my investment but I feel it will be 2018 before we get an idea where we are at, whether it be good or bad. In 4-6 weeks we will have first quarter numbers and we can all start bitchin again.
Gross margin for the three and nine-month periods ended December 31, 2016 was 42% and 41% respectively, compared to 26% and 30% for the same periods in 2015, driven by increased business volume and pricing adjustments.
Hopefully that will be addressed during the question and answer session on Monday.
Good find!
Yea I'd like to see more volume. All we can do is watch the next half hour as well as the next 2 trading days. Dow Jones mentioned Kite as a potential takeover target today and it's up 6 bucks (8%) a share as of about 10 minutes ago. Keep your fingers crossed for Monday's report.
WHOA Buckaroos, we've got a little rally going
I also scratched my head on that one this morning. Another nice day for CYRX and a great day for KITE, up over 23% today.
No problem. I thought I had missed a company announcement.
YES
Where did you get that info?
GREAT MOVE!
Shelf filing?
If something's "brewing" your 3 mil. quarter estimate may look good.
$50,000,000 offering heating up?
http://ih.advfn.com/p.php?pid=nmona&article=73714744&symbol=CYRX
You nailed it!
I would be happy with a 2.5 million dollar quarter but if you guys say it's 3 million I'll go along with you.
Don't worry, George will straighten this out.